2022
Ketones: the double-edged sword of SGLT2 inhibitors?
Lupsa BC, Kibbey RG, Inzucchi SE. Ketones: the double-edged sword of SGLT2 inhibitors? Diabetologia 2022, 66: 23-32. PMID: 36255460, DOI: 10.1007/s00125-022-05815-1.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsBlood GlucoseDiabetes Mellitus, Type 2HumansKetonesSodium-Glucose Transporter 2 InhibitorsConceptsSGLT2 inhibitorsDrug categoriesSodium-glucose cotransporter 2 inhibitorsCardio-renal benefitsNormal blood glucose concentrationsCotransporter 2 inhibitorsClasses of medicationsAnti-inflammatory effectsSerious adverse effectsType 1 diabetesBlood glucose levelsBlood glucose concentrationKidney outcomesRare complicationBlood pressureSGLT2 inhibitionGlucose levelsKetone levelsBody weightType 2Ketone bodiesAdverse effectsGlucose concentrationInhibitorsEdged sword
2019
Personalized Management of Type 2 Diabetes
Peter PR, Lupsa BC. Personalized Management of Type 2 Diabetes. Current Diabetes Reports 2019, 19: 115. PMID: 31686226, DOI: 10.1007/s11892-019-1244-0.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsBlood GlucoseDiabetes Mellitus, Type 2Disease ManagementHumansHypoglycemic AgentsPrecision MedicineConceptsType 2 diabetesManagement of patientsUnique patient characteristicsSpecific patient subpopulationsClass of agentsGlycemic targetsTreatment landscapeMedical therapyPatient characteristicsPharmacotherapeutic optionsPatient subpopulationsIndividualized carePersonalized managementClinical practiceType 2ReviewOur goalRecent FindingsWePatientsDiabetesTherapyManagementPhysiciansCare
2018
Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits
Lupsa BC, Inzucchi SE. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Diabetologia 2018, 61: 2118-2125. PMID: 30132031, DOI: 10.1007/s00125-018-4663-6.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsBenzhydryl CompoundsBlood GlucoseBlood PressureBody WeightBone and BonesCanagliflozinCardiovascular DiseasesDiabetes Mellitus, Type 2Diabetic KetoacidosisGlucosidesHumansHypoglycemic AgentsKetosisKidneyNeoplasmsRandomized Controlled Trials as TopicRisk AssessmentSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 InhibitorsWeight LossConceptsSGLT2 inhibitorsSodium-glucose cotransporter 2 inhibitorsPostprandial blood glucose levelsEuglycaemic diabetic ketoacidosisGlucose-lowering medicationsCotransporter 2 inhibitorsDiabetic kidney diseaseGenitourinary tract infectionsLower extremity amputationHigh-risk individualsBlood glucose levelsPlasma glucose concentrationCardiovascular outcomesDiabetic ketoacidosisUrinary frequencyTract infectionsOptimal prescribingNew drug categoryKidney diseaseGlucose reabsorptionGlucose levelsHigh riskDrug categoriesBody weightBone fractures
2010
Treatment of Type B Insulin Resistance: A Novel Approach to Reduce Insulin Receptor Autoantibodies
Malek R, Chong AY, Lupsa BC, Lungu AO, Cochran EK, Soos MA, Semple RK, Balow JE, Gorden P. Treatment of Type B Insulin Resistance: A Novel Approach to Reduce Insulin Receptor Autoantibodies. The Journal Of Clinical Endocrinology & Metabolism 2010, 95: 3641-3647. PMID: 20484479, PMCID: PMC2913034, DOI: 10.1210/jc.2010-0167.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdrenal Cortex HormonesAdultAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedAutoantibodiesBlood GlucoseCyclophosphamideDrug Therapy, CombinationFemaleHumansHyperandrogenismHyperglycemiaImmunosuppressive AgentsInsulin ResistanceMaleMiddle AgedReceptor, InsulinRituximabTreatment OutcomeConceptsType B insulin resistanceInsulin resistanceAmelioration of hyperglycemiaPathogenic autoantibody productionSerious adverse eventsRare autoimmune disorderInitiation of treatmentForm of immunosuppressionInsulin receptor autoantibodiesSevere acanthosis nigricansAdverse eventsInsulin therapyMedication regimenPulse corticosteroidsInsulin doseReceptor autoantibodiesAutoantibody productionAcanthosis nigricansAutoimmune disordersGlycated hemoglobinStandardized treatmentTreatment protocolEndocrine parametersPatientsSteroids results